Stock Scorecard
Stock Summary for Cel-Sci Corp (CVM) - $1.51 as of 4/23/2024 10:27:19 AM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CVM
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CVM
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CVM
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for CVM
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Financial Details for CVM
Company Overview |
|
---|---|
Ticker | CVM |
Company Name | Cel-Sci Corp |
Country | USA |
Description | CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/10/2024 |
Stock Price History |
|
Last Day Price | 1.51 |
Last Day Price Updated | 4/23/2024 10:27:19 AM EST |
Last Day Volume | 123,706 |
Average Daily Volume | 245,672 |
52-Week High | 3.23 |
52-Week Low | 1.04 |
Last Price to 52 Week Low | 45.19% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 59.15 |
Sector PE | 60.50 |
5-Year Average PE | -9.42 |
Free Cash Flow Ratio | 25.17 |
Industry Free Cash Flow Ratio | 18.38 |
Sector Free Cash Flow Ratio | 29.99 |
Current Ratio Most Recent Quarter | 1.26 |
Total Cash Per Share | 0.06 |
Book Value Per Share Most Recent Quarter | 0.25 |
Price to Book Ratio | 6.96 |
Industry Price to Book Ratio | 7.50 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 11,797.42 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.49 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 53,979,000 |
Market Capitalization | 81,508,290 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | 8/28/1996 |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 62.50 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | 0.00% |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 12.28% |
Reported EPS 12 Trailing Months | -0.69 |
Reported EPS Past Year | -0.14 |
Reported EPS Prior Year | -0.72 |
Net Income Twelve Trailing Months | -31,050,318 |
Net Income Past Year | -32,194,303 |
Net Income Prior Year | -36,700,681 |
Quarterly Revenue Growth YOY | -62.70% |
5-Year Revenue Growth | 18.29% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 3,241,440 |
Total Cash Past Year | 250,000 |
Total Cash Prior Year | 22,672,138 |
Net Cash Position Most Recent Quarter | 3,241,440 |
Net Cash Position Past Year | 250,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 13,214,890 |
Total Stockholder Equity Prior Year | 32,163,207 |
Total Stockholder Equity Most Recent Quarter | 12,650,260 |
Options |
|
Put/Call Ratio | 0.10 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.15 |
MACD Signal | -0.14 |
20-Day Bollinger Lower Band | 1.39 |
20-Day Bollinger Middle Band | 2.25 |
20-Day Bollinger Upper Band | 3.10 |
Beta | 1.17 |
RSI | 33.46 |
50-Day SMA | 2.04 |
200-Day SMA | 7.48 |
System |
|
Modified | 4/22/2024 10:09:46 PM EST |